Translocation and cyclin D (TC) molecular classification of multiple myeloma.
| Group . | Primary Ig TLC . | Cyclin D . | Hyperdiploid * . | Prevalence, % . | Survival CC, %† . | Survival HDT, %† . |
|---|---|---|---|---|---|---|
| * There is not an absolute correlation of the groups with the presence or absence of hyperdiploidy. | ||||||
| †5-year overall survival with conventional chemotherapy (CC),14 and predicted 5-year overall survival with high-dose therapy (HDT). 23 | ||||||
| ‡ The results likely represent a composite group of TC2 and TC3. | ||||||
| TC1 | 11q13 | D1 | No | 15 | 38 | 88 |
| 6p21 | D3 | No | 3 | |||
| TC2 | None | D1 lo | Yes | 43 | ||
| 30‡ | 50‡ | |||||
| TC3 | None | D2 | ? | 17 | ||
| TC4 | 4p16 | D2 | No | 15 | 10 | 23 |
| TC5 | 16q23 | D2 | No | 5 | 13 | |
| 20q11 | D2 | No | 2 | |||
| Group . | Primary Ig TLC . | Cyclin D . | Hyperdiploid * . | Prevalence, % . | Survival CC, %† . | Survival HDT, %† . |
|---|---|---|---|---|---|---|
| * There is not an absolute correlation of the groups with the presence or absence of hyperdiploidy. | ||||||
| †5-year overall survival with conventional chemotherapy (CC),14 and predicted 5-year overall survival with high-dose therapy (HDT). 23 | ||||||
| ‡ The results likely represent a composite group of TC2 and TC3. | ||||||
| TC1 | 11q13 | D1 | No | 15 | 38 | 88 |
| 6p21 | D3 | No | 3 | |||
| TC2 | None | D1 lo | Yes | 43 | ||
| 30‡ | 50‡ | |||||
| TC3 | None | D2 | ? | 17 | ||
| TC4 | 4p16 | D2 | No | 15 | 10 | 23 |
| TC5 | 16q23 | D2 | No | 5 | 13 | |
| 20q11 | D2 | No | 2 | |||